Bharat Biotech’s Covaxin has showcased 77.8 per cent efficacy against symptomatic Covid-19 and presents no safety concerns as detailed by a study published in The Lancet. The interim study was funded by Bharat Biotech and the Indian Council of Medical Research and partly authored by officials at both bodies.
Covaxin, which uses traditional, inactivated-virus technology, “induces a robust antibody response” two weeks after two doses are given, mentioned The Lancet in a statement. The medical journal further added that no severe-vaccine-related deaths or adverse events were recorded during a randomized trial involving 24,419 participants aged 18-97 years between Nov. 2020 and May 2021 in India. Covaxin was recently granted emergency usage approval by the World Health Organization.
The Lancet, however, has added that more research would be necessary to discover Covaxin’s long-term safety and effectiveness, as well as protection against hospitalisation, death, along with its ability to fend off Covid delta variant and other variants of concern.